In the accompanying comment letter (1), Weinert summarizes published data from the Brazilian Gestational Diabetes Study (2) and comments on applying International Association of Diabetes and Pregnancy Study Groups (IADPSG) Consensus Panel recommendations (3) for the diagnosis of gestational diabetes mellitus (GDM) to that cohort.
The Brazilian study provided evidence that adverse perinatal outcomes are associated with levels of maternal glycemia below those diagnostic of GDM by American Diabetes Association or World Health Organization criteria. However, the results were potentially confounded by the treatment of GDM. It did find that women with GDM were at increased risk for some outcomes, but did not define diagnostic thresholds as suggested by Weinert. Due to space limitations, this study was not cited in the IADPSG report (3). However, at the June 2008 IADPSG International Workshop Conference on Gestational Diabetes Diagnosis and Classification in Pasadena, California, Dr. Maria Ines-Schmidt, principal investigator of the Brazilian study, presented an unpublished analysis of associations of maternal fasting plasma glucose and 75-g 1-h and 2-h postload glucose with perinatal outcomes. Although the study sample size was not nearly as large as that of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, associations tended to be similar (4).
Weinert also focuses on the fact that the IADPSG recommended criteria diagnose a greater proportion as GDM than other criteria. The major reason for this is that the IADPSG diagnosis of GDM only requires that one or more values meets or exceeds a threshold; most other strategies require at least two abnormal values for the diagnosis. In addition, as noted in the IADPSG report (3), relatively small changes in glucose thresholds, especially for fasting plasma glucose, result in large differences in proportions diagnosed as GDM.
Weinert states that in the analysis of Brazilian results, 1-h and 2-h 75-g oral glucose tolerance test values “virtually overlapped for predicting fetal macrosomia and composite outcome.” This is offered in support of a shorter 1-h test. As Weinert indicated, FPG and 1-h thresholds identified a large majority of GDM women in the HAPO study cohort. However, as indicated in the IADPSG report (3), the 2-h threshold identified a small proportion of women not detected by fasting and 1-h thresholds who were at increased risk of adverse outcomes.
The primary focus of the IADPSG Consensus Panel was to recommend diagnostic threshold values that identified clinically significant risk for adverse pregnancy outcome. We feel that goal was achieved with the strategy for detection and diagnosis of GDM that was recommended.
Acknowledgments
No potential conflicts of interest relevant to this article were reported.
B.E.M. contributed to the discussion, wrote the manuscript, and reviewed/edited the manuscript. S.G.G. reviewed/edited the manuscript. B.P. reviewed/edited the manuscript. L.P.L. wrote the manuscript and reviewed/edited the manuscript. A.R.D. reviewed/edited the manuscript. J.J.N.O. reviewed/edited the manuscript. T.A.B. reviewed/edited the manuscript.
- © 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.